CN110656162A - Detection method of circulating miR-1290 - Google Patents
Detection method of circulating miR-1290 Download PDFInfo
- Publication number
- CN110656162A CN110656162A CN201910878912.1A CN201910878912A CN110656162A CN 110656162 A CN110656162 A CN 110656162A CN 201910878912 A CN201910878912 A CN 201910878912A CN 110656162 A CN110656162 A CN 110656162A
- Authority
- CN
- China
- Prior art keywords
- mir
- reverse transcription
- seq
- primer
- circulating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/686—Polymerase chain reaction [PCR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
Abstract
The invention discloses a detection method of circulating miR-1290, which comprises the following steps: (1) extracting circulating miRNA from the detected sample plasma or serum; (2) reverse transcription by a stem-loop method: carrying out reverse transcription on the miRNA obtained in the step (1) by a specific stem-loop method; (3) and (3) qPCR detection: and (3) carrying out qPCR detection by using the cDNA obtained in the step (2) as a template. The invention has relatively low cost and good sensitivity and specificity. Can be used for relevant basic and application research works of human, animals and the like.
Description
Technical Field
The invention relates to the field of biomedicine, and in particular relates to a method for detecting circulating miR-1290.
Background
MicroRNA (miRNA) is a non-coding single-stranded small RNA with the length of about 19-23 nucleotides, widely exists in various organisms and is an important regulatory factor. mirnas regulate gene expression at the post-transcriptional level by complementarily pairing with target mrnas, degrading the target mrnas or inhibiting translation. The miRNA has high conservative property and strict space-time specificity, forms a complex regulation network with a target mRNA molecule thereof, and participates in various life activities including cell proliferation, apoptosis, cell differentiation, development, stress response and the like. mirnas play an important role in the development of tumors.
Research shows that miRNA can stably exist in various body fluids such as serum, plasma and the like, the miRNA is called circulating miRNA, is closely related to the occurrence and development of tumors, and can be used as an important marker for tumor screening, high-risk population prediction and treatment effect evaluation. Circulating mirnas are derived primarily from two pathways: passive leakage of tissue damage or apoptotic necrotic cells and active secretion of cell-derived microvesicles. Circulating mirnas exist independently of the cell, but have higher stability, probably due to annealing of RNA to DNA and thus resistance to both DNase and RNase degradation, or protection of RNA by inclusion in lipid or lipoprotein complexes, or by chemical modification or binding to proteins.
The existing miRNA detection methods mainly comprise Northern blot analysis, real-time fluorescence quantitative PCR (polymerase chain reaction), DNA microarray chips, second-generation sequencing and the like. The Northern blot analysis method is simple and easy to implement, but has low sensitivity, long time consumption, poor repeatability and larger required total RNA amount, and is not suitable for the detection of circulating miRNA. The microarray chip can perform high-throughput miRNA analysis, but still needs enough initial sample amount and has low sensitivity. The second-generation sequencing technology can also realize high-throughput detection of miRNA, but has higher detection cost and is not suitable for clinical analysis of large samples.
The qPCR detection is realized by adding a fluorescent group into a PCR reaction system and utilizing fluorescent signal accumulation to monitor the whole PCR process in real time, thereby realizing quantitative and qualitative analysis of the initial unknown content template. Compared to Northern blot and microarray analysis, qPCR requires a smaller amount of sample and significantly improves the detection range and sensitivity. However, since mirnas are very small, specially designed primers are required to achieve PCR detection. There are two main ways at present: poly (A) caudate and stem-loop methods. The poly (A) tailing method uses poly (A) polymerase to make a poly (A) sequence on the 3' end of miRNA, and then uses oligo (dT) sequence primer to do reverse transcription. Due to the universality of the reverse transcription primer, the detection cost is reduced, and the sensitivity and the specificity of detection are also reduced. The stem-loop method carries out reverse transcription on miRNA through a stem-loop primer, and because the 5 'end of the stem-loop primer contains a stem-loop structure and the 3' end of the stem-loop primer has 6 specific bases matched with the 3 'end of mature miRNA, short mature miRNA molecules can be expanded and a specific 3' primer site is added, so that the reverse transcription reaction can be carried out specifically.
Circulating miRNA detection is important content of liquid biopsy, and has important value for early diagnosis, curative effect evaluation and prognosis monitoring of tumors. Imaoka et al (Annals of Oncology 27: 1879-. The research of Ang Li et al (Clincancer Res; 19(13) J mu Ly 1,2013) finds that miR-1290 is remarkably increased in pancreatic cancer serum, the areas of the working curves (ROC) of the subjects of pancreatic cancer patients, chronic pancreatitis patients and pancreatic neuroendocrine tumor patients are respectively 0.96, 0.81 and 0.80, and circulating miR-1290 can be used as an early diagnosis marker of pancreatic cancer. The research of France sca Tavano et al (Sci Rep; 8 (1)) Nov 6,2018 shows that the combined detection of plasma miR-1290 and CA 19-9 has stronger diagnosis and identification efficiency than the separate detection of the two. Circulating miR-1290 is therefore a potential tumor marker.
Disclosure of Invention
The invention aims to provide a detection method of circulating miR-1290, which is a detection method for quantifying the circulating miR-1290 by combining stem-loop reverse transcription and taqman probe real-time fluorescence quantitative PCR.
The adopted technical scheme is as follows:
a method for detecting circulating miR-1290, comprising the following steps of:
(1) extracting circulating miRNA from the detected sample plasma or serum;
(2) reverse transcription by a stem-loop method: carrying out reverse transcription on the miRNA obtained in the step (1) by a specific stem-loop method;
(3) and (3) qPCR detection: and (3) carrying out qPCR detection by using the cDNA obtained in the step (2) as a template.
Further, in the step (1), the extraction of the circulating miRNA is performed by a nucleic acid adsorption column.
Further, in the step (2), the reverse transcription system comprises a reverse transcription buffer solution, a reverse transcriptase, a reverse transcription primer, nuclease-free pure water and a miRNA template; the reverse transcription primer contains a specific stem-loop structure for accurately distinguishing highly homologous miRNAs; the nucleotide sequence of the reverse transcription primer aiming at the miR-1290 is shown as SEQ ID No. 1; the reaction conditions for reverse transcription were: bathing at 16 deg.C for 30min, at 37 deg.C for 30min, heating at 85 deg.C for 5min to inactivate enzyme, and storing at 4 deg.C.
Further, the total volume of the reverse transcription system was 20. mu.L, wherein 10. mu.L of reverse transcription buffer, 1.5. mu.L of reverse transcriptase, 1. mu.L of reverse transcription primer, and 7.5. mu.L of miRNA template diluted with nuclease-free pure water.
Further, in the step (3), the reaction system for qPCR detection comprises: the kit comprises a Taqman premix, a specific forward primer, a universal reverse primer, a Taqman probe, nuclease-free pure water and a cDNA template; the nucleotide sequences of the specific forward primer, the Taqman probe and the universal reverse primer aiming at the miR-1290 are respectively shown as SEQ ID No.2, SEQ ID No.3 and SEQ ID No. 10; the reaction conditions for the qPCR assay were: pre-denaturation at 95 ℃ for 2.5min, denaturation at 95 ℃ for 15s, annealing at 60 ℃ for 30s, extension at 72 ℃ for 1min, 40 cycles, and finally extension at 72 ℃ for 10 min.
Furthermore, the total volume of the reaction system for qPCR detection was 10. mu.L, wherein 5. mu.L of Taqman premix, 0.2. mu.L of specific forward primer (10mM), 0.2. mu. L, Taqman probe (10mM) for universal reverse primer (10mM), and 4.2. mu.L of cDNA template diluted in pure water without nuclease.
Further, in the step (1), an internal reference system is added, wherein the internal reference system comprises: internal references miR-16-5p and cel-miR-39 as well as corresponding reverse transcription primers, qPCR forward primers and Taqman probes,
the nucleotide sequence of the reverse transcription primer of miR-16-5p is shown as SEQ ID No.4,
the nucleotide sequence of the qPCR forward primer of miR-16-5p is shown in SEQ ID No.5,
the nucleotide sequence of the Taqman probe of miR-16-5p is shown in SEQ ID No.6,
the nucleotide sequence of the reverse transcription primer of cel-miR-39 is shown in SEQ ID No.7,
the nucleotide sequence of the qPCR forward primer of cel-miR-39 is shown in SEQ ID No.8,
the nucleotide sequence of the Taqman probe of cel-miR-39 is shown in SEQ ID No. 9;
the nucleotide sequence of miR-16-5p is shown in SEQ ID No. 12;
the nucleotide sequence of cel-miR-39 is shown in SEQ ID No. 13.
Further, the internal reference cel-miR-39 is an internal reference cel-miR-39 solution which is added in the sample extraction process and has the volume of 2 mu L, and the concentration is 0.2 uM.
A kit, which is prepared into a miR-1290 analysis kit by using the detection method of circulating miR-1290 in any scheme.
The application of the circulating miR-1290 detection method in any one of the schemes is to detect the miR-1290 expression level of a serum or plasma sample for basic research and clinical application.
The invention has the beneficial effects that:
the method is suitable for detecting the expression level of miR-1290 from the organism liquid sample with low miRNA abundance, and has relatively low cost, good sensitivity and specificity. According to the invention, the detection method can be prepared into a miR-1290 assay kit for in vitro detection and identification.
The detection method can be used for relevant basic and application research works of human, animals and the like.
The implementation of the invention has important social and economic benefits on the research, prevention and treatment and the like of the pathogenesis of malignant tumor seriously harming human health.
Drawings
FIG. 1 is an amplification curve of different concentrations of miR-1290 standard, with standard concentrations from left to right of 100nM, 10nM, 1nM, 100pM, 10pM and 1pM, respectively. In FIG. 1, RFU is relative fluorescence unit; cycles is the number of Cycles; amplification curve.
FIG. 2 is a standard curve for the miR-1290 standard.
FIG. 3 is a comparison of miR-1290 expression levels between serum and plasma samples from the same patient. Numbers N188, N189, N191, N192, N197, T45 and G112 are for different patients, respectively.
FIG. 4 is the relative expression levels of miR-1290 in different clinical samples.
Detailed Description
The invention is described in further detail below for the purpose of further understanding, but the scope of the invention is not limited thereto.
The detection method of the circulating miR-1290 mainly comprises the following three steps:
(1) extracting circulating miRNA from the detected sample plasma or serum;
(2) reverse transcription by a stem-loop method: carrying out reverse transcription on the miRNA obtained in the step (1) by a specific stem-loop method;
(3) and (3) qPCR detection: and (3) carrying out qPCR detection by using the cDNA obtained in the step (2) as a template.
In step (1):
1. the sample is serum or plasma; it may be preferred that the sample is serum.
2. Can select proper internal parameters
miR-16-5p is selected as an internal reference, and cel-miR-39 is exogenously added as another internal reference in the process of extracting nucleic acid. The sequence of miR-16-5p is shown in SEQ ID No.12, and the sequence of cel-miR-39 is shown in SEQ ID No. 13.
The internal reference cel-miR-39 solution is biosynthesized by Ruibo, the preparation concentration is 20um, and the use concentration is 10 nM.
In step (2):
3. design of specific Stem-Loop reverse transcription primers
Selecting a proper stem-loop sequence, adding a specific base paired with the 3 ' end of the mature miRNA sequence at the tail end, thereby forming a reverse transcription primer of which the 5 ' end contains a stem-loop structure, and the 3 ' end is provided with the specific base complementarily paired with the mature miRNA sequence, thereby expanding the short mature miRNA molecule and increasing the specific primer and probe binding site. The reverse transcription primers of each miRNA are respectively SEQ ID No.1, SEQ ID No.4 and SEQ ID No. 7.
The primers used were synthesized by Biotechnology engineering (Shanghai).
4. Design of specific qPCR primers and Taqman probes
According to the sequence and stem-loop sequence information of miR-1290, miR-16-5p and cel-miR-39, a specific upstream primer is designed, and the Tm values are ensured to be similar as much as possible (about 59 ℃). Meanwhile, a specific Taqman probe is designed, a modifying group at the 5 'end is 6-FAM, and a modifying group at the 3' end is TAMRA-N.
The probes used were synthesized by Biotechnology engineering (Shanghai).
5. Reverse transcription
The invention adopts miRNA first strand cDNA synthesis kit (NO: B532453) of biological engineering (Shanghai) company for reverse transcription. The reaction system comprises: mu.L of 2 XmiRNA L-RT Solution mix, 1.5. mu.L of miRNA-L-RT Enzyme mix, 1.0. mu.L of reverse transcription primer (10uM) and 7.5. mu.L of template, totaling 20. mu.L. The reaction conditions include 16 deg.C bath for 30min, 37 deg.C bath for 30min, 85 deg.C heating for 5min to inactivate enzyme, and 4 deg.C storage.
In step (3):
qPCR reaction and optimization of reaction conditions
The invention adopts the universal PCR downstream primer on the basis of the stem-loop reverse transcription, thereby reducing the experiment cost. Conventional Taqman premix (containing buffer, dNTPs Mix, regular Taq enzyme and MgCl) was used in the PCR process2Solution) also increases the selectivity of the reagent. The technology of the invention has the advantages of strong specificity, high sensitivity, low cost, relatively simple operation and the like.
In conclusion, the invention adopts Taq PCR premix of Biotechnology engineering (Shanghai) company to carry out qPCR reaction. Optimizing a reaction system and reaction conditions to finally determine the optimal reaction system as follows: mu.L of Taq qPCR mix, 0.2. mu.L of specific forward primer (10uM), 0.2. mu.L of universal reverse primer (10uM), 0.4. mu.L of specific probe (10uM) and 4.2. mu.L of cDNA template, for a total of 10. mu.L. The reaction conditions are pre-denaturation at 95 ℃ for 2.5min, denaturation at 95 ℃ for 15s, annealing at 60 ℃ for 30s, extension at 72 ℃ for 1min, 40 cycles, and finally extension at 72 ℃ for 10min, wherein the annealing temperature can be within the range of 50-60 ℃.
The invention is further illustrated by the following specific examples. Before describing the examples, the sample sources used for the various examples are described below in a unified manner:
the main sample sources of the invention are as follows:
peripheral blood samples were obtained from the second hospital affiliated with the Zhejiang university medical college. The serum/plasma collection procedure was: collecting blood in blood collecting tube containing coagulant, centrifuging at 3000rpm and 4 deg.C for 10min, and collecting supernatant (namely serum) for storage. Collecting blood in a blood collection tube containing an EDTA anticoagulant tube, centrifuging at 3000rpm and 4 ℃ for 10min, and taking supernatant in a 1.5ml centrifuge tube; centrifuging at 16000g and 4 deg.C for 10min, collecting supernatant (plasma), and storing. Serum/plasma samples were aliquoted and stored at-80 ℃.
Example 1: detecting the expression level of miR-1290 in a serum/plasma sample by taking miR-16-5p and cel-miR-39 as internal references
1. Extraction of miRNA from serum/plasma
miRNA in Serum/Plasma is extracted by using miRNeasy Serum/Plasma Advanced Kit (ID: 217204) of QIAGEN company, and the operation method is referred to the Kit instruction and is optimized.
(1) Putting 200 μ L of serum/plasma sample into a 1.5ml centrifuge tube, adding 60 μ L of Buffer RPL, mixing uniformly by vortex for 10s, and standing at room temperature for 3 min; (2) adding 20 mu L of Buffer RPP into each centrifuge tube, uniformly mixing by vortex for 30s, and standing for 3min at room temperature; (3)12000 Xg, centrifuging for 3min at room temperature; (4) the supernatant was aspirated into a new 1.5ml centrifuge tube, and an equal amount of isopropanol (about 230. mu.L) was added and mixed well; (5) adding the solution into an adsorption column, centrifuging at 12000 Xg for 15s at room temperature, repeatedly passing through the column for 1 time, and pouring out the liquid in the collection tube; (6) adding 700 mu L of Buffer RWT and 500 mu L of Buffer RPE into the adsorption column in sequence, and centrifuging at room temperature for 15s, and pouring off the liquid in the collection tube; (7) adding 500 μ L80% ethanol, 12000 Xg into adsorption column, and centrifuging at room temperature for 2 min; (8) replacing a new collecting pipe, and opening the cover at the maximum rotating speed for centrifuging for 5 min; (9) replacing a 1.5ml centrifuge tube as a collecting tube, adding 20 mu L DEPC treated water to the center of each adsorption film, and standing at room temperature for 2 min; (10) centrifuging at the maximum speed for 1min, and collecting RNA solution.
Then miR-16-5p is selected as an internal reference, and meanwhile, cel-miR-39 is exogenously added as another internal reference in the process of extracting nucleic acid in the steps (1) - (10). The internal reference system comprises: internal references miR-16-5p and cel-miR-39 and corresponding reverse transcription primers, qPCR forward primers and Taqman probes.
The sequence of miR-16-5p is shown in SEQ ID No.12, and the sequence of cel-miR-39 is shown in SEQ ID No. 13.
The nucleotide sequence of the reverse transcription primer of miR-16-5p is shown as SEQ ID No.4,
the nucleotide sequence of the qPCR forward primer of miR-16-5p is shown in SEQ ID No.5,
the nucleotide sequence of the Taqman probe of miR-16-5p is shown in SEQ ID No.6,
the nucleotide sequence of the reverse transcription primer of cel-miR-39 is shown in SEQ ID No.7,
the nucleotide sequence of the qPCR forward primer of cel-miR-39 is shown in SEQ ID No.8,
the nucleotide sequence of the Taqman probe of cel-miR-39 is shown in SEQ ID No. 9.
The internal reference cel-miR-39 solution is biosynthesized by Ruibo, the preparation concentration is 20um, and the use concentration is 10 nM.
2. Design of specific Stem-Loop reverse transcription primers
Selecting a proper stem-loop sequence, adding a specific base paired with the 3 ' end of the mature miRNA sequence at the tail end, thereby forming a reverse transcription primer of which the 5 ' end contains a stem-loop structure, and the 3 ' end is provided with the specific base complementarily paired with the mature miRNA sequence, thereby expanding the short mature miRNA molecule and increasing the specific primer and probe binding site. The reverse transcription primers of each miRNA are respectively SEQ ID No.1, SEQ ID No.4 and SEQ ID No. 7.
The primers used were synthesized by Biotechnology engineering (Shanghai).
3. Design of specific qPCR primers and Taqman probes
According to the sequence and stem-loop sequence information of miR-1290, miR-16-5p and cel-miR-39, a specific upstream primer is designed, and the Tm values are ensured to be similar as much as possible (about 59 ℃). Meanwhile, a specific Taqman probe is designed, a modifying group at the 5 'end is 6-FAM, and a modifying group at the 3' end is TAMRA-N.
The probes used were synthesized by Biotechnology engineering (Shanghai).
4. Reverse transcription
Reverse transcription was performed using a miRNA first strand cDNA Synthesis kit (NO: B532453) from Biotechnology (Shanghai) Inc. A reverse transcription system (20 mu L) is prepared according to the instruction (the following table 1), and miR-1290, miR-16-5p and cel-miR-39 are respectively used for reverse transcription. Reverse transcription conditions: bathing at 16 deg.C for 30min, at 37 deg.C for 30min, heating at 85 deg.C for 5min to inactivate enzyme, and storing at 4 deg.C.
TABLE 1
| Components | Content (wt.) |
| 2×miRNA L-RT Solution mix | 10μL |
| miRNA-L-RT Enzyme mix | 1.5μL |
| Reverse transcription primer (10uM) | 1.0μL |
| MiRNA template | 7.5μL |
qPCR detection
The qPCR reaction was carried out using Taq PCR premix (NO: B110006) from Biotechnology (Shanghai). The reverse transcription product was diluted to an appropriate concentration, and a reaction system (10. mu.L) was prepared according to the instructions (Table 2 below), and 3 duplicate wells were provided for each sample. Carrying out qPCR reaction by taking miR-16-5p and cel-miR-39 as internal references, wherein a PCR running instrument is Bio-Rad CFX96, and the reaction conditions are as follows: pre-denaturation at 95 ℃ for 2.5min, denaturation at 95 ℃ for 15s, annealing at 60 ℃ for 30s, extension at 72 ℃ for 1min, 40 cycles, and finally extension at 72 ℃ for 10 min.
TABLE 2
The nucleotide sequences of the specific forward primer, the Taqman probe and the universal reverse primer aiming at the miR-1290 are respectively shown as SEQ ID No.2, SEQ ID No.3 and SEQ ID No. 10.
6. Data analysis and results
And (3) calculating a delta Ct value by taking miR-16-5p and cel-miR-39 as internal references, and analyzing the expression level of the miRNAs in the sample. Relative expression in this example was calculated as 2 Δ Ct, data analysis was performed using GraphPad Prism7 software, Student's tset, and final results are expressed as mean ± SD (standard deviation).
2△△CtIn the values, Δ Ct ═ Ct (miR-1290) -Ct (miR-16-5p, cel-miR-39);
delta Ct ═ delta Ct (sample to be tested) -. delta Ct (normal control)
Example 2: quantitative amplification detection of miR-1290
Preparation and dilution of miR-1290 standard substance
The miR-1290 Standard (MiDETECTTM miRNA qRT-PCR Standard RNA) is biosynthesized by Bomb, and has a sequence of SEQ ID No. 11. The total amount of the standard substance is 1nmol, and water is added to prepare the standard substance miRNA with the final concentration of 10um, and the miRNA is subpackaged and stored at-80 ℃. At the same time, samples were taken and serially subjected to gradient dilution to prepare standards at concentrations of 100nM, 10nM, 1nM, 100pM, 10pM and 1pM, respectively.
2. Drawing of standard curve and quantitative detection of miR-1290
Serum mirnas were extracted and reverse transcribed as in example 1 above. In the qPCR detection, the 7 standards are simultaneously detected. And drawing a standard curve according to the concentration and Ct value of the standard substance, and calculating the expression level of miR-1290 in the sample to be detected according to the standard curve. The amplification curve and the standard curve of the miR-1290 standard product are shown in figures 1 and 2.
Example 3: methodology evaluation (recovery test)
1. Addition of standards
After 60. mu.L of Buffer RPL was added, vortexed for 10s and allowed to stand at room temperature for 3min as in example 1 above, the high, medium and low concentrations of miR-1290 standards (1204000000 copy number, 120400000 copy number and 12040000 copy number) were added to the serum samples, respectively.
Detection of miR-1290 expression level and calculation of recovery rate
And extracting miRNA in serum in the same step, and carrying out qPCR quantitative detection after reverse transcription. And calculating the copy number of the miR-1290 in each group of samples according to the standard curve. The recovery results are shown in Table 5.
TABLE 3 recovery of samples from each group with high, medium and low concentration standards
| Sample (I) | Copy number of added standard | Recovering the copy number | Recovery |
| Control group | |||
| 0 | 58479603.74 | — | |
| Sample + Low concentration Standard | 1204000000 | 1115751731 | 0.878132996 |
| Sample + medium concentration standard substance | 120400000 | 198074269.5 | 1.159424134 |
| Sample + high concentration standard | 12040000 | 70998961.56 | 1.039813772 |
Example 4: comparative detection of serum and plasma samples
1. Collecting a sample
Simultaneously collecting serum and plasma samples of the same patient, centrifuging the same steps, respectively collecting serum and plasma, subpackaging and storing at-80 ℃.
2. Detection of miR-1290 in sample
miRNA in serum and plasma samples were extracted by the same procedure as in example 1, and subjected to qPCR detection after reverse transcription. Comparative analysis the expression level difference of miR-1290 between serum and plasma samples (see FIG. 3 for results). The results show that both serum and plasma samples can be used for qPCR detection of miR-1290, but the detected Ct value of miR-1290 in serum is significantly lower than that of plasma, which indicates that the expression amount of miR-1290 in serum is higher than that of plasma.
Example 5: clinical sample testing
1. Collecting a sample
10 pancreatic cancers, 10 gastric cancers (all tumor patients were pathologically diagnosed by a skilled pathologist, had not previously suffered from other tumors, and had not been treated with chemotherapy or radiotherapy) and 50 healthy persons (normal controls, none of the tumor-free benign patients) were collected. Collecting fresh procoagulant blood 5ml on empty stomach, centrifuging at 3000rpm and 4 deg.C for 10min, collecting upper layer serum, and storing at-80 deg.C.
2. Detection of miR-1290 expression level in serum
Referring to the steps in example 1, miRNA in serum is extracted, reverse transcription is carried out, and qPCR detection is carried out by taking cel-miR-39 as an internal reference. The expression level difference of miR-1290 among different clinical samples is analyzed in comparison (the result is shown in figure 4).
The above-described examples represent only a few of the principal embodiments of the invention.
The above-listed detailed description is only a specific description of a possible embodiment of the present invention, and they are not intended to limit the scope of the present invention, and equivalent embodiments or modifications made without departing from the technical spirit of the present invention should be included in the scope of the present invention.
Sequence listing
<110> Zhejiang university
<120> detection method of circulating miR-1290
<160> 13
<170> SIPOSequenceListing 1.0
<210> 1
<211> 50
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 1
gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgactccctg 50
<210> 2
<211> 21
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 2
gccgcgtgga tttttggatc a 21
<210> 3
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 3
<210> 4
<211> 50
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 4
gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgaccgccaa 50
<210> 5
<211> 21
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 5
gcgcgtagca gcacgtaaat a 21
<210> 6
<211> 19
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 6
cgcactggat acgaccgcc 19
<210> 7
<211> 52
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 7
gtcgtatcca gtgcagggtc cgaggtattc gcactggata cgaccaagct ga 52
<210> 8
<211> 18
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 8
ggcgtcaccg ggtgtaaa 18
<210> 9
<211> 22
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 9
cagcttggtc gtatccagtg cg 22
<210> 10
<211> 20
<212> DNA
<213> Artificial Sequence (Artificial Sequence)
<400> 10
<210> 11
<211> 19
<212> RNA
<213> Artificial Sequence (Artificial Sequence)
<400> 11
uggauuuuug gaucaggga 19
<210> 12
<211> 22
<212> RNA
<213> Artificial Sequence (Artificial Sequence)
<400> 12
uagcagcacg uaaauauugg cg 22
<210> 13
<211> 22
<212> RNA
<213> Artificial Sequence (Artificial Sequence)
<400> 13
ucaccgggug uaaaucagcu ug 22
Claims (10)
1. A method for detecting circulating miR-1290, which is characterized by comprising the following steps:
(1) extracting circulating miRNA from the detected sample plasma or serum;
(2) reverse transcription by a stem-loop method: carrying out reverse transcription on the miRNA obtained in the step (1) by a specific stem-loop method;
(3) and (3) qPCR detection: and (3) carrying out qPCR detection by using the cDNA obtained in the step (2) as a template.
2. The method for detecting circulating miR-1290 according to claim 1, wherein in the step (1), the extraction of circulating miRNA is realized by a nucleic acid adsorption column.
3. The detection method of circulating miR-1290 according to claim 1, characterized in that in the step (2), the reverse transcription system comprises a reverse transcription buffer, a reverse transcriptase, a reverse transcription primer, nuclease-free pure water and a miRNA template; the reverse transcription primer contains a specific stem-loop structure for accurately distinguishing highly homologous miRNAs; the nucleotide sequence of the reverse transcription primer aiming at the miR-1290 is shown as SEQ ID No. 1; the reaction conditions for reverse transcription were: bathing at 16 deg.C for 30min, at 37 deg.C for 30min, heating at 85 deg.C for 5min to inactivate enzyme, and storing at 4 deg.C.
4. The method for detecting circulating miR-1290 according to claim 3, wherein the total volume of a reverse transcription system is 20 μ L, wherein the reverse transcription buffer solution is 10 μ L, the reverse transcriptase is 1.5 μ L, the reverse transcription primer is 1 μ L, and the miRNA template diluted by nuclease-free pure water is 7.5 μ L.
5. The method for detecting circulating miR-1290 according to claim 1, wherein in the step (3), the reaction system for qPCR detection comprises: the kit comprises a Taqman premix, a specific forward primer, a universal reverse primer, a Taqman probe, nuclease-free pure water and a cDNA template; the nucleotide sequences of the specific forward primer, the Taqman probe and the universal reverse primer aiming at the miR-1290 are respectively shown as SEQ ID No.2, SEQ ID No.3 and SEQ ID No. 10; the reaction conditions for the qPCR assay were: pre-denaturation at 95 ℃ for 2.5min, denaturation at 95 ℃ for 15s, annealing at 60 ℃ for 30s, extension at 72 ℃ for 1min, 40 cycles, and finally extension at 72 ℃ for 10 min.
6. The detection method of the circulating miR-1290 according to claim 5, characterized in that the total volume of the reaction system for qPCR detection is 10 μ L, wherein 5 μ L of Taqman premix, 0.2 μ L specific forward primer (10mM), 0.2 μ L, Taqman probe (10mM) universal reverse primer (10mM) and 4.2 μ L cDNA template diluted by nuclease-free pure water are used.
7. The method for detecting circulating miR-1290 according to claim 1, wherein in the step (1), an internal reference system is added, and the internal reference system comprises: internal references miR-16-5p and cel-miR-39 as well as corresponding reverse transcription primers, qPCR forward primers and Taqman probes,
the nucleotide sequence of the reverse transcription primer of miR-16-5p is shown as SEQ ID No.4,
the nucleotide sequence of the qPCR forward primer of miR-16-5p is shown in SEQ ID No.5,
the nucleotide sequence of the Taqman probe of miR-16-5p is shown in SEQ ID No.6,
the nucleotide sequence of the reverse transcription primer of cel-miR-39 is shown in SEQ ID No.7,
the nucleotide sequence of the qPCR forward primer of cel-miR-39 is shown in SEQ ID No.8,
the nucleotide sequence of the Taqman probe of cel-miR-39 is shown in SEQ ID No. 9;
the nucleotide sequence of miR-16-5p is shown in SEQ ID No. 12;
the nucleotide sequence of cel-miR-39 is shown in SEQ ID No. 13.
8. The method for detecting the circulating miR-1290 according to claim 7, wherein the internal reference cel-miR-39 is a 2-microliter solution of internal reference cel-miR-39 added in the sample extraction process, and the concentration is 0.2 uM.
9. A kit, which is prepared into a miR-1290 assay kit by the method for detecting circulating miR-1290 according to any one of claims 1 to 8.
10. The use of the circulating miR-1290 assay of a serum or plasma sample for the detection of miR-1290 expression level for basic research and clinical application according to the method for detecting miR-1290 of any one of claims 1-8.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910878912.1A CN110656162A (en) | 2019-09-18 | 2019-09-18 | Detection method of circulating miR-1290 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910878912.1A CN110656162A (en) | 2019-09-18 | 2019-09-18 | Detection method of circulating miR-1290 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110656162A true CN110656162A (en) | 2020-01-07 |
Family
ID=69037240
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910878912.1A Pending CN110656162A (en) | 2019-09-18 | 2019-09-18 | Detection method of circulating miR-1290 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110656162A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104059994A (en) * | 2014-07-15 | 2014-09-24 | 江苏省疾病预防控制中心 | Kit based on serum miRNA as well as use method and application of kit |
| CN106591487A (en) * | 2017-02-22 | 2017-04-26 | 西北工业大学 | Serum microRNA diagnostic marker for osteoportic fractures in old people and diagnostic kit thereof |
| CN107075573A (en) * | 2014-07-30 | 2017-08-18 | 莫尔研究应用有限公司 | Method of prognosis and treatment system for ALL |
-
2019
- 2019-09-18 CN CN201910878912.1A patent/CN110656162A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104059994A (en) * | 2014-07-15 | 2014-09-24 | 江苏省疾病预防控制中心 | Kit based on serum miRNA as well as use method and application of kit |
| CN107075573A (en) * | 2014-07-30 | 2017-08-18 | 莫尔研究应用有限公司 | Method of prognosis and treatment system for ALL |
| CN106591487A (en) * | 2017-02-22 | 2017-04-26 | 西北工业大学 | Serum microRNA diagnostic marker for osteoportic fractures in old people and diagnostic kit thereof |
Non-Patent Citations (3)
| Title |
|---|
| APPLIED BIOSYSTEM: "Taqman Advanced miRNA Assay-superior performance for miRNA detection and quantitatification", 《WHITE PAPER》 * |
| JIA WU等: "Up-regulation of microRNA-1290 impairs cytokinesis and affects the reprogramming of colon cancer cells", 《CANCER LETTERS》 * |
| 王奇峰: "血浆microRNA用于结直肠癌诊断的研究及miR-202-3p抑制结直肠癌生长的机制研究", 《中国博士学位论文全文数据库 医药卫生科技辑》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7358434B2 (en) | Urine Biomarker Cohorts, Gene Expression Characteristics, and Methods of Their Use | |
| CN105316341B (en) | A kind of LncRNA and its application in marker or prostate cancer prognosis recurrence marker is detected as prostate cancer | |
| WO2009143379A2 (en) | Use of extracellular rna to measure disease | |
| EP2406402A2 (en) | Method to assess human allograft status from microrna expression levels | |
| CN108949992B (en) | Biomarker related to esophageal squamous carcinoma and grading thereof | |
| WO2013095941A1 (en) | Methods and kits for detecting subjects at risk of having cancer | |
| CN113201591B (en) | Application of long-chain non-coding RNA and inhibitor thereof in preventing and treating breast cancer | |
| CN107519193B (en) | Molecular diagnostic marker for early stage esophageal squamous carcinoma and application thereof | |
| CN107312852A (en) | Myocardial infarction diagnosis mark compositions | |
| CN111304326B (en) | Reagent for detecting and targeting lncRNA biomarker and application of reagent in hepatocellular carcinoma | |
| CN106755293B (en) | Lung cancer auxiliary diagnosis related lncRNA marker and application thereof | |
| CN112980947A (en) | Primer and kit for detecting circulating microRNA (microribonucleic acid) related to lung cancer diagnosis and treatment | |
| CN108866187B (en) | Long-chain non-coding RNA marker related to lung cancer auxiliary diagnosis and application thereof | |
| KR102096498B1 (en) | MicroRNA-4732-5p for diagnosing or predicting recurrence of colorectal cancer and use thereof | |
| CN113201537B (en) | Long-chain non-coding RNA for cisplatin resistance diagnosis of triple-negative breast cancer and application thereof | |
| CN107312851A (en) | Myocardial infarction biomarker miR 1283 | |
| Zhou et al. | A method for extracting and characterizing RNA from urine: For downstream PCR and RNAseq analysis | |
| CN109563548B (en) | In vitro method for identifying pancreatic cancer or intraductal papillary myxoma of pancreas | |
| CN110656162A (en) | Detection method of circulating miR-1290 | |
| Lee et al. | MicroRNA-23a: a novel serum based diagnostic biomarker for lung adenocarcinoma | |
| KR20130098669A (en) | Serum mirna as a marker for the diagnosis of lymph node metastasis of gastric cancer | |
| US11021756B2 (en) | MiRNA markers for the diagnosis of osteosarcoma | |
| CN113774138B (en) | Kit, device and method for lung cancer diagnosis | |
| CN107164550A (en) | A kind of reagent for detecting myocardial infarction and its application | |
| CN107858427B (en) | Application of miR-429 in preparation of breast cancer diagnosis and detection kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20200107 |
|
| RJ01 | Rejection of invention patent application after publication |